About Pellsys Pharma
Pellsys Pharma is a Healthcare company based in Hyderabad (India). It manufactures and supplies pellet-based pharmaceutical products. It operates on a B2B model. The company has 14 employees. Its Indian entity Pellsys Pharma Private Limited reported revenue of ₹29.54 Cr. Its focus areas include Pharmaceuticals, Manufacturing and Drug Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Pellsys Pharma manufactures and supplies pellet-based pharmaceutical products through providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug formulation. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Hyderabad, India
- Employees 14
- SectorsHealthcare
- Website pellsyspharma.com
- Legal Name Pellsys Pharma Private Limited
- Date of Incorporation 19 Dec, 2008
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹29.54 Cr
FY 2025 · -3% YoY
- Net Profit₹19.4 Lakh
FY 2025 · 1% margin
- EBITDA₹1.44 Cr
FY 2025 · 5% margin
- Employee Count14
Associated legal entities of Pellsys Pharma
Pellsys Pharma operates through Pellsys Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Pellsys Pharma Private Limited CIN U24233TG2008PTC062293 | Active | 19 Dec 2008 | Hyderabad, Telangana | ₹29.5 Cr | 14 | 4 | View details |
Board of directors of Pellsys Pharma Private Limited (Pellsys Pharma)
Pellsys Pharma Private Limited is the primary company behind Pellsys Pharma. The board of Pellsys Pharma Private Limited currently have 4 directors; the longest-serving is Cherupalli Ganesh, appointed in 2008. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Cherupalli Ganesh DIN 01890988 | Whole-time director | 19 Dec 2008 | 17 yrs 10 mo | Pellsys Pharma Private Limited |
| Srinulakshmi Perumallu Chaladi DIN 00725510 | Managing Director | 19 Dec 2008 | 17 yrs 10 mo | Pellsys Pharma Private Limited |
| Venugopal Setty Sarvisetty DIN 01167752 | Director | 09 Jul 2013 | 13 yrs 4 mo | Pellsys Pharma Private Limited |
| Ramesh Babu Sarvisetty DIN 01167790 | Whole-time director | 09 Jul 2013 | 13 yrs 4 mo | Pellsys Pharma Private Limited |
Financials of Pellsys Pharma
Figures of Pellsys Pharma Private Limited, the primary company behind Pellsys Pharma, for FY 2025. Revenue was ₹29.54 Cr (-3% year on year). Net profit was ₹19.4 Lakh (1% margin). EBITDA was ₹1.44 Cr (5% margin). Revenue has grown at a compounded annual rate of -6% over three years and +8% over five years.
- ₹29.54 CrRevenue · FY 2025 · -3% YoY
- ₹19.4 LakhNet profit · 1% margin
- ₹1.44 CrEBITDA · 5% margin
- ₹2.32 CrPaid-up capital
- 14Employees (provident fund records)
- -6%Revenue CAGR, 3 years
- +8%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Pellsys Pharma Private Limited are on its company page.
Detailed financial statements for Pellsys Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Pellsys Pharma
Pellsys Pharma has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Pellsys Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pellsys Pharma
Pellsys Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Pellsys Pharma has 14 employees.
The primary company behind Pellsys Pharma, Pellsys Pharma Private Limited, reported revenue of ₹29.54 Cr for FY 2025, down 3% year on year.
Pellsys Pharma manufactures and supplies pellet-based pharmaceutical products through providing healthcare solutions, producing pharmaceutical products, producing manufactured goods, and drug formulation. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Pellsys Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Pellsys Pharma operates through Pellsys Pharma Private Limited.
The legal entities of Pellsys Pharma currently have 4 directors, including Venugopal Setty Sarvisetty, Cherupalli Ganesh, Ramesh Babu Sarvisetty and others.